Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a glass of pomegranate juice tame gut inflammation?

NCT ID NCT03000101

Disease control Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial investigates whether drinking pomegranate juice for 12 weeks can reduce gut inflammation in people with Crohn's disease or ulcerative colitis who are in remission. Participants will drink either pomegranate juice or a placebo beverage twice daily, and researchers will measure changes in fecal calprotectin, a marker of intestinal inflammation, along with other inflammatory indicators. The goal is to see if this natural drink could help keep inflammation in check.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
100% pomegranate juice
What this could lead to
If effective, drinking pomegranate juice could become a simple dietary addition to help manage inflammation in people with inflammatory bowel disease.
What could go wrong
This is a small early-stage trial, so results may not apply broadly. The juice may not significantly lower inflammation, and it is not a replacement for standard medical therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Started

Jan 2017

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic, and histologic criteria) in clinical remission (SCCAI = 0) from at least three months and in stable therapy (without therapeutic modifications in the three previous months) with mesalazine, immunomodulators and/or biologics. * Patients affected by Crohn's Disease, particularly involving sigmoid colon and rectum (diagnosed on the base of clinic, endoscopic, and histologic criteria) in clinical remission (CDAI \< 150) from at least three months and in stable therapy (without therapeutic modifications in the three previous months) with mesalazine A, immunomodulators and/or biologics. * Fecal calprotectin at baseline ≥ 100 microg/g. * Signed informed consent. Exclusion Criteria: * Patients affected by Ulcerative Colitis and Crohn's Disease with severe endoscopic disease activity (Ulcerative Colitis: Mayo Endoscopic Score = 3; Crohn's Disease: Simple Endoscopic Score SES-CD \> 15). * Patients on steroid therapy in the two previous months. * Patients in therapy with warfarin or other anticoagulants. * Known or supposed hypersensitivity to fruit and/or juice of pomegranate. * Women in fertile age which refuse to use contraceptives specified in the study (oral contraception, IUD) and breastfeed women. * Diabetic patients and other patients with severe clinical conditions which the investigator consider to contraindicate patient participation at the study. * Therapy modifications and/or assumption of experimental therapies within three months before the study inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colitis colonic disorder Crohn disease Digestive System Diseases digestive system disorder gastroenteritis Inflammation inflammatory bowel disease intestinal disorder ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn's disease Ulcerative colitis

Contacts and locations

Locations

  • U.O. Gastroenterologia - Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi

    Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.